Clinical trial
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
NCT00093470 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 18, 2004
- Completion date
- April 14, 2015
- Enrollment
- 144 (actual)
- Sites
- 341
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute megakaryoblastic leukemia, adult acute monocytic leukemia, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with maturation, adult acute myeloid leukemia with minimal differentiation, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22.3;q23.3); mllt3-kmt2a, adult acute myeloid leukemia without maturation, adult acute myelomonocytic leukemia, adult erythroleukemia, adult pure erythroid leukemia, alkylating agent-related acute myeloid leukemia, myelodysplastic syndrome with excess blasts, recurrent adult acute myeloid leukemia